MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
64.84
+2.71
+4.36%
Opening 15:13 03/31 EDT
OPEN
62.95
PREV CLOSE
62.13
HIGH
64.89
LOW
62.87
VOLUME
820.51K
TURNOVER
--
52 WEEK HIGH
82.22
52 WEEK LOW
47.50
MARKET CAP
7.68B
P/E (TTM)
25.35
1D
5D
1M
3M
1Y
5Y
1D
Is Halozyme Therapeutics (HALO) Pricing Reflect Its Potential After Recent Share Price Pullback
Simply Wall St · 8h ago
Weekly Report: what happened at HALO last week (0323-0327)?
Weekly Report · 1d ago
A Look At Halozyme Therapeutics (HALO) Valuation After Mixed Quarterly Earnings And Guidance
Simply Wall St · 4d ago
Is Halozyme’s Interim CFO Appointment Shaping The ENHANZE Royalty Story For Halozyme Therapeutics (HALO)?
Simply Wall St · 5d ago
Halozyme Interim CFO David A. Ramsay files initial beneficial ownership statement
Reuters · 03/23 22:35
Halozyme Therapeutics Inc. Announces Annual Stockholders Meeting
Reuters · 03/23 20:13
Weekly Report: what happened at HALO last week (0316-0320)?
Weekly Report · 03/23 09:04
Could Halozyme (HALO) Returning David Ramsay as Interim CFO Reframe Its ENHANZE Royalty Story?
Simply Wall St · 03/17 01:18
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.